Evolocumab
- Generic Name
- Evolocumab
- Brand Names
- Repatha
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1256937-27-5
- Unique Ingredient Identifier
- LKC0U3A8NJ
- Background
Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies....
- Indication
Evolocumab is indicated in adult patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is also indicated as an adjunct to diet, alone or in combination with other hypolipidemic treatments, in adults with primary hyperlipidemia (and in pediatric patients ≥10 years old with hete...
- Associated Conditions
- Coronary Revascularization, Myocardial Infarction, Stroke, Increases in serum total low-density lipoprotein (LDL)
- Associated Therapies
- -
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Interventions
- Drug: AtezolizumabDrug: DocetaxelDrug: RO6958688Drug: CPI-444Drug: LinagliptinDrug: Sacituzumab GovitecanDrug: BevacizumabDrug: CamonsertibDrug: CobimetinibDrug: IpatasertibDrug: PemetrexedDrug: EvolocumabDrug: TiragolumabOther: RadiationDrug: TocilizumabDrug: CarboplatinDrug: GemcitabineDrug: XL092
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT03337698
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan
Impact of LDL-cholesterol Lowering on Platelet Activation
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 4
- Registration Number
- NCT03331666
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Inova Health Care Services
- Target Recruit Count
- 4
- Registration Number
- NCT03258281
- Locations
- 🇺🇸
Inova Fairfax Hospital, Falls Church, Virginia, United States
Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Inova Health Care Services
- Target Recruit Count
- 30
- Registration Number
- NCT03247972
- Locations
- 🇺🇸
Inova Fairfax Hospital, Falls Church, Virginia, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03193047
- Locations
- 🇺🇸
L-MARC Research Center, Louisville, Kentucky, United States
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
- Conditions
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 259
- Registration Number
- NCT03096288
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1600
- Registration Number
- NCT03080935
- Locations
- 🇧🇪
Centre Hospitalier Universitaire Brugmann, Brussels, Belgium
🇧🇪Algemeen Ziekenhuis Sint Lucas, Gent, Belgium
🇧🇪Imelda Ziekenhuis vzw, Bonheiden, Belgium
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 382
- Registration Number
- NCT03060577
- Locations
- 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom
Evolocumab Pregnancy Exposure Registry
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 140
- Registration Number
- NCT02957604
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Marja-Riitta Taskinen
- Target Recruit Count
- 14
- Registration Number
- NCT02948777
- Locations
- 🇫🇮
Helsinki University Hospital, Biomedicum 2U, Helsinki, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.